Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Fluicell AB's annualized net income for the quarter that ended in Mar. 2026 was kr13.24 Mil. Fluicell AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr1.51 Mil. Therefore, Fluicell AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 874.24%.
The historical rank and industry rank for Fluicell AB's Return-on-Tangible-Equity or its related term are showing as below:
OSTO:FLUI'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -390.53 Med: -117.83 Max: -56.34
Current: -56.34
During the past 11 years, Fluicell AB's highest Return-on-Tangible-Equity was -56.34%. The lowest was -390.53%. And the median was -117.83%.
OSTO:FLUI's Return-on-Tangible-Equity is ranked worse than 58.16% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs OSTO:FLUI: -56.34
Fluicell AB (OSTO:FLUI) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Fluicell AB Return-on-Tangible-Equity Related Terms
Fluicell AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Fluicell AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Fluicell AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Fluicell AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 874.24% mean?
Fluicell AB (OSTO:FLUI) has a Return-on-Tangible-Equity of 874.24% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #695 out of 1195 companies in the Biotechnology industry, placing it in the top 58.2%.
Is Fluicell AB's Return-on-Tangible-Equity too high?
Fluicell AB's current Return-on-Tangible-Equity is 874.24%. Based on the distribution chart, Fluicell AB ranks #695 out of 1195 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fluicell AB has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #695 out of 1195 companies for Return-on-Tangible-Equity. This places Fluicell AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Fluicell AB and its competitors. Fluicell AB's current Return-on-Tangible-Equity is 874.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Fairly Valued. The stock's GF Value™ is kr34.46, compared to a current price of kr35.80 — trading 3.9% above its estimated fair value. The current Return-on-Tangible-Equity is 874.24%. Fluicell AB's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Return-on-Tangible-Equity is 874.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be overvalued.
The current stock price of kr35.80 is trading 3.9% above its estimated GF Value™ of kr34.46.
GuruFocus considers Fluicell AB to be Fairly Valued.
Key valuation signals for OSTO:FLUI:
Return-on-Tangible-Equity: 874.24%
GF Value™: kr34.46 vs. price of kr35.80 (3.9% above fair value)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
50GF Score
Get the complete analysis for OSTO:FLUI
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
